{"filings":[{"id":69282,"accession_number":"0001295947-26-000013","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-05-13T20:35:45+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer reports FY26 adj EPS $4.38; acquires LaCorium Health for $150M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["FY26 revenue $1,088.7M (-4.3% YoY); adjusted diluted EPS $4.38 vs $4.52 prior year.","Q4 revenue $281.6M (-5% YoY); adjusted diluted EPS $1.23 vs $1.32.","Acquiring LaCorium Health (Australian therapeutic skincare) for ~$150M cash; expected close Q2 FY27.","LaCorium TTM revenue ~$40M; expected ~$12M EBITDA with synergies.","FY27 outlook: organic revenue growth 1-3%, adj EPS $4.42-$4.51, FCF $250M+."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102418,"accession_number":"0001104659-26-032332","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-03-20T23:59:59+00:00","items":["1.01","7.01","8.01","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare to acquire Breathe Right brand portfolio for $1.045B","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition includes Breathe Right, Dimetapp, Anbesol brands; trailing revenue $200M, EBITDA $95M.","Purchase price $1.045B cash; net ~$900M after $150M anticipated tax benefits.","Implied multiple of 11.0x EBITDA (9.5x net of tax benefits); accretive to gross/EBITDA margins and EPS.","Expected pro-forma net leverage ~4.0x at closing; target below 3.0x by fiscal 2028.","Transaction expected to close in first half fiscal 2027, subject to HSR clearance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":102417,"accession_number":"0001295947-26-000006","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q3 revenue $283.4M, down 2.4% YoY; adjusted EPS $1.14 vs $1.22","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $0.97; adjusted diluted EPS $1.14 (down from $1.22); net income $46.7M.","Narrowed FY2026 revenue outlook to ~$1.1B from $1.1-1.115B; adjusted EPS ~$4.54.","Repurchased ~0.8M shares in Q3 for $45.8M; YTD repurchases ~2.3M shares at $155.6M.","Closed acquisition of eye care supplier Pillar5 Pharma in December 2025.","Clear Eyes supply constraints continue; management expects supply improvements in coming quarters."],"consensus_eps_estimate":null,"consensus_eps_actual":2.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":807088000.0,"consensus_period":"2026-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":118691,"accession_number":"0001295947-25-000037","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Q2 adj EPS $1.07 beats prior year; raises FY adj EPS guidance to $4.54-$4.58","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $274.1M (-3.4% YoY); diluted EPS $0.86 vs $1.09; adjusted EPS $1.07.","Raises FY2026 adjusted diluted EPS outlook to $4.54-$4.58 (high end of prior range).","Repurchased ~1.1M shares in Q2 for $75M; cumulative 1.6M shares in H1 for $109.8M.","Clear Eyes supply constraints drove OTC revenue decline; expects improvement in H2 via capacity rebuild.","Free cash flow guidance reaffirmed at $245M+; covenant leverage 2.4x."],"consensus_eps_estimate":null,"consensus_eps_actual":1.81,"consensus_revenue_estimate":null,"consensus_revenue_actual":523644000.0,"consensus_period":"2026-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":135202,"accession_number":"0001295947-25-000027","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["1.01","2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q1 revenue down 6.6%, misses; acquires Pillar5 for CAD 150M, cuts FY26 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $249.5M (-6.6% YoY); diluted EPS $0.95 ($0.90 adjusted).","Clear Eyes supply constraints drove North American OTC revenue down to $212.6M.","Acquiring Pillar5 Pharma for CAD 150M cash; expected to close Q3 FY2026.","FY2026 outlook cut: revenue now $1.10-1.115B, EPS $4.50-4.58 (from $4.70-4.82).","Net debt ~$0.9B; leverage 2.4x; free cash flow guidance unchanged at $245M+."],"consensus_eps_estimate":1.4039,"consensus_eps_actual":0.95,"consensus_revenue_estimate":null,"consensus_revenue_actual":249530000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":152177,"accession_number":"0001295947-25-000014","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-05-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q4 revenue $296.5M, adj EPS $1.32; FY25 adj EPS $4.52; FY26 outlook $4.70-4.82","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $296.5M (+7.0% YoY, organic +7.9%); diluted EPS $1.00 GAAP, adjusted $1.32 (vs $1.02 prior year).","FY2025 revenue $1,137.8M (+1.1%); diluted EPS $4.29 GAAP, adjusted $4.52 (+7.4% vs $4.21 prior year).","Free cash flow $243.3M in FY2025 (+1.6% YoY); leverage ratio reduced to 2.4x at year-end.","Initial FY2026 outlook: organic revenue growth ~1-2%, diluted EPS $4.70-4.82, free cash flow $245M or more.","Management guides mid-to-high single-digit EPS growth despite ~$15M tariff headwind."],"consensus_eps_estimate":1.1557,"consensus_eps_actual":4.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":1137762000.0,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171008,"accession_number":"0001295947-25-000007","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-02-06T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Q3 FY2025 EPS $1.22 (+15% YoY); raises FY25 adjusted EPS outlook to ~$4.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenues $290.3M (+2.7% YoY); record quarterly sales and EPS.","Diluted EPS $1.22 vs $1.06 prior year; net income $61.0M vs $53.0M.","Raises FY25 adjusted EPS outlook to ~$4.50 from $4.40-$4.46; FCF ≥$240M reaffirmed.","International OTC segment grew 11.3% (8.3% ex-FX); North American OTC +1.0%.","Leverage reduced to 2.5x; repurchased 0.6M shares for ~$40.2M YTD."],"consensus_eps_estimate":0.98,"consensus_eps_actual":3.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":841244000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":171007,"accession_number":"0001104659-25-001076","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare expands CFO Christine Sacco's role to include COO, effective immediately","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christine Sacco, CFO since 2016, appointed COO/CFO effective Jan 6, 2025; will oversee supply chain.","New compensation: base salary $700k, target cash incentive 75% of salary, LTIP target $1.575M.","Received a $1.575M time-based RSU retention award cliff vesting in 4 years.","No family relationships or arrangements with other persons for her appointment disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":187983,"accession_number":"0001295947-24-000030","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Healthcare Q2 revenue $283.8M, diluted EPS $1.09; reaffirms FY2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $283.8M (-0.9% YoY) slightly ahead of expectations; diluted EPS $1.09 vs $1.07 prior year.","North American OTC down 1.9% to $239.8M; International OTC up 5.0% to $44.0M driven by Hydralyte.","Free cash flow $67.8M in Q2; net cash from operations $69.8M, up 11.7% YoY.","Repurchased ~0.2M shares for $12M in Q2; reduced debt by $75M YTD; leverage ratio 2.7x.","Reaffirmed FY2025 outlook: revenue $1,125-1,140M, adj. diluted EPS $4.40-4.46, free cash flow $240M+."],"consensus_eps_estimate":1.0102,"consensus_eps_actual":2.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":550927000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":204485,"accession_number":"0001295947-24-000023","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2024-08-08T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"Prestige Consumer Q1 revenue $267.1M beats expectations; reaffirms FY2025 outlook","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 GAAP EPS $0.98, adjusted EPS $0.90; revenue down 4.4% YoY but ahead of internal plan.","Cash from operations $54.8M (+13.9% YoY); reduced debt $35M and repurchased $26M in shares.","North American OTC revenue $232.3M (-5.6%); International OTC $34.8M (+5.0% driven by Hydralyte).","FY2025 guidance reaffirmed: revenue $1.125-$1.140B, adjusted EPS $4.40-$4.46, FCF $240M+.","CEO cited earlier supply of Clear Eyes products as primary driver of Q1 beat over expectations."],"consensus_eps_estimate":null,"consensus_eps_actual":0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":267142000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221286,"accession_number":"0001295947-24-000015","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2024-05-14T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Prestige Consumer Q4 revenue down 2.9%; adj. EPS $1.02; $300M buyback; FY2025 EPS guidance $4.40-$4.46","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $277.0M (-2.9% ex-FX); non-GAAP adj. diluted EPS $1.02 vs $1.07 prior year.","Full-year FY2024 revenue $1,125.4M (flat); GAAP diluted EPS $4.17; non-GAAP diluted EPS $4.21.","Leverage ratio improved to 2.8x, below 3x target; net debt ~$1.1B.","Board authorized new $300M share repurchase program; timing subject to market conditions.","Initial FY2025 guidance: organic revenue growth ~1%, diluted EPS $4.40-$4.46, free cash flow $240M+."],"consensus_eps_estimate":null,"consensus_eps_actual":4.17,"consensus_revenue_estimate":null,"consensus_revenue_actual":1125357000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":221285,"accession_number":"0001104659-24-058841","cik":1295947,"company_name":"Prestige Consumer Healthcare Inc.","ticker":"PBH","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Prestige Consumer Healthcare elects John F. Kelly, former Pfizer VP, to Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John F. Kelly, former Vice President Quality Operations and EHS at Pfizer, elected to PBH Board on May 7, 2024.","Appointed to Compensation and Talent Management and Nominating and Corporate Governance Committees.","Kelly retired in 2022 after 40-year career at Pfizer, including leading global quality and EHS functions.","No related party transactions or arrangements in connection with his appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2292339118.9353633,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}